JANX
Janux Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Janux Therapeutics (JANX) Stock: Buy, Sell, or Hold?
$11.68
-0.71 (-5.73%)
▼
5d:
-27.27%
30d:
-31.82%
90d:
-27.54%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
42/100
Position
OVERSOLD
30-Day Fair Range
$14.78 – $18.49
Position: OVERSOLD
Forward P/E & Valuation
-4.8x
Next 12M consensus est.
Wall Street Target
$32.47
+162.0% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$11.54 / $18.33
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: JANX is down 27.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 2, 2026 at $17.52 · last confirmed Nov 9, 2026
Strength: 7.5/10
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $11.68, which is considered oversold relative to its 30-day fair value range of $14.78 to $18.49.
Technical Outlook: Technically, JANX is showing sideways momentum. The price is currently testing key support at $11.54. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: JANX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.47 (+162.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JANX is showing sideways momentum. The price is currently testing key support at $11.54. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: JANX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.47 (+162.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.78 -
$18.49
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$14.78 -
$18.49
Current vs Trading Range
OVERSOLD
Support Level
$11.54
Resistance Level
$18.33
Current Trend
Sideways
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 162.0% below Wall St target ($32.47)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-4.84
Wall Street Target
$32.47
(+162.0%)
Revenue Growth (YoY)
-7.1%
Share JANX Analysis
Share this live JANX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (JANX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Janux Therapeutics reported deep B-cell depletion in its initial Phase 1 trial of JANX011, causing a significant stock decline according to a bullish trader on StockTwits.
Key Retail Themes:
Company News
Clinical Trials
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 51 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 39 SELL |
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$304 | 36 SELL |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 67 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive JANX Research Pages
